These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

979 related items for PubMed ID: 8899189

  • 21. Prognostic factors affecting leukemia relapse after allogeneic BMT conditioned with cyclophosphamide and fractionated TBI.
    Zapatero A, Martín de Vidales C, Pinar B, Rodríguez F, Marín A, Cerezo L, Domínguez P, Pérez Torrubia A.
    Bone Marrow Transplant; 1996 Sep; 18(3):591-6. PubMed ID: 8879623
    [Abstract] [Full Text] [Related]

  • 22. Allogeneic bone marrow transplantation after hyperfractionated total-body irradiation and cyclophosphamide in children with acute leukemia.
    Brochstein JA, Kernan NA, Groshen S, Cirrincione C, Shank B, Emanuel D, Laver J, O'Reilly RJ.
    N Engl J Med; 1987 Dec 24; 317(26):1618-24. PubMed ID: 3317056
    [Abstract] [Full Text] [Related]

  • 23. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, Finkenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Kuse R, Braumann D, Metzner B, del Valle F, Erttmann R, Kabisch H, Zander AR.
    Bone Marrow Transplant; 2000 Oct 24; 26(7):711-6. PubMed ID: 11042650
    [Abstract] [Full Text] [Related]

  • 24. Effect of induced GVHD in leukemia patients relapsing after allogeneic bone marrow transplantation: single-center experience of 33 adult patients.
    Min CK, Eom KS, Lee S, Kim DW, Lee JW, Min WS, Kim CC.
    Bone Marrow Transplant; 2001 May 24; 27(9):999-1005. PubMed ID: 11436112
    [Abstract] [Full Text] [Related]

  • 25. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
    Shigematsu A, Kondo T, Yamamoto S, Sugita J, Onozawa M, Kahata K, Endo T, Shiratori S, Ota S, Obara M, Wakasa K, Takahata M, Takeda Y, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M.
    Biol Blood Marrow Transplant; 2008 May 24; 14(5):568-75. PubMed ID: 18410899
    [Abstract] [Full Text] [Related]

  • 26. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR, German Cooperative Transplant Study Group.
    Ann Hematol; 2003 Jun 24; 82(6):336-42. PubMed ID: 12728337
    [Abstract] [Full Text] [Related]

  • 27. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors.
    Demuynck H, Verhoef GE, Zachee P, Emonds MP, van der Schueren E, van den Berghe H, Vandenberghe P, Casteels-Van Daele M, Boogaerts MA.
    Bone Marrow Transplant; 1996 May 24; 17(5):745-51. PubMed ID: 8733692
    [Abstract] [Full Text] [Related]

  • 28. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T, Aisa Y, Watanabe R, Yamazaki R, Kato J, Shimizu T, Shigematsu N, Kubo A, Yajima T, Hibi T, Ikeda Y, Okamoto S.
    Biol Blood Marrow Transplant; 2008 Jun 24; 14(6):651-7. PubMed ID: 18489990
    [Abstract] [Full Text] [Related]

  • 29. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.
    Carlens S, Ringdén O, Aschan J, Hägglund H, Ljungman P, Mattsson J, Remberger M.
    Clin Transplant; 1998 Apr 24; 12(2):84-92. PubMed ID: 9575394
    [Abstract] [Full Text] [Related]

  • 30. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M, Perrin MC, Belhabri A, Molina L, Nicolini F, Tigaud JD, Sotto JJ, Guyotat D, Fière D, Archimbaud E.
    Bone Marrow Transplant; 1999 Jan 24; 23(2):145-50. PubMed ID: 10197799
    [Abstract] [Full Text] [Related]

  • 31. Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies.
    Wu DP, Milpied N, Moreau P, Mechinaud-Lacroix F, Mahe B, Le Tortorec S, Rapp MJ, Bourdin S, Mahe JM, Harousseau JL.
    Bone Marrow Transplant; 1994 Nov 24; 14(5):751-7. PubMed ID: 7889008
    [Abstract] [Full Text] [Related]

  • 32. Long-term follow-up of allogeneic bone marrow transplantation for patients with chronic phase chronic myeloid leukemia prepared with a regimen consisting of cyclophosphamide, cytarabine and single-dose total body irradiation conditioning.
    Zaretsky Y, Rifkind J, Lockwood G, Tsang R, Kiss T, Hasegawa W, Fyles G, Tejpar I, Loach D, Minden M, Messner H, Lipton JH.
    Bone Marrow Transplant; 2007 Sep 24; 40(5):423-30. PubMed ID: 17603516
    [Abstract] [Full Text] [Related]

  • 33. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.
    Lamparelli T, Van Lint MT, Gualandi F, Occhini D, Barbanti M, Sacchi N, Ficai G, Ghinatti C, Ferrara GB, Delfino L, Pozzi S, Morabito A, Zikos P, Vitale V, Corvo R, Frassoni F, Bacigalupo A.
    Bone Marrow Transplant; 1997 Dec 24; 20(12):1057-62. PubMed ID: 9466278
    [Abstract] [Full Text] [Related]

  • 34. Long-term results of bone marrow transplantation for patients with AML, ALL and CML prepared with single dose total body irradiation of 500 cGy delivered with a high dose rate.
    Fyles GM, Messner HA, Lockwood G, Curtis JE, Rider W, Minden MD, Meharchand JM, Lipton J, Tritchler D, Van Dyk J.
    Bone Marrow Transplant; 1991 Dec 24; 8(6):453-63. PubMed ID: 1790425
    [Abstract] [Full Text] [Related]

  • 35. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia.
    Jillella AP, Doria R, Khan K, Zelterman D, Ahmad YH, Smith BR, Holmes W, Becker P, Roberts KB, Rappeport JM.
    Bone Marrow Transplant; 1999 Jun 24; 23(11):1095-100. PubMed ID: 10382947
    [Abstract] [Full Text] [Related]

  • 36. Unrelated donor bone marrow transplantation using a chemotherapy-only preparative regimen for adults with high-risk acute myelogenous leukemia.
    Ayash LJ, Ratanatharathorn V, Braun T, Silver SM, Reynolds CM, Uberti JP.
    Am J Hematol; 2007 Jan 24; 82(1):6-14. PubMed ID: 16986128
    [Abstract] [Full Text] [Related]

  • 37. Unrelated donor bone marrow transplantation as treatment for chronic myeloid leukemia: the Spanish experience. The Chronic Myeloid Leukemia Subcommittee of the GETH. Grupo Español de Trasplante Hemopoyético.
    Carreras E, Tomás JF, Sanz G, Iriondo A, Boqué C, López J, Cabrera R, Sureda A, de Soria VG, Sierra J, Sanz MA, Torres A.
    Haematologica; 2000 May 24; 85(5):530-8. PubMed ID: 10800172
    [Abstract] [Full Text] [Related]

  • 38. Matched unrelated donor marrow transplantation in patients with advanced acute leukemia.
    Greinix HT, Reiter E, Schulenburg A, Keil F, Lechner K, Fischer G, Rosenmayr A, Leitner G, Kalhs P.
    Bone Marrow Transplant; 1998 Dec 24; 22 Suppl 4():S53-6. PubMed ID: 9916636
    [Abstract] [Full Text] [Related]

  • 39. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group.
    Arnold R, de Witte T, van Biezen A, Hermans J, Jacobsen N, Runde V, Gratwohl A, Apperley JF.
    Bone Marrow Transplant; 1998 Jun 24; 21(12):1213-6. PubMed ID: 9674854
    [Abstract] [Full Text] [Related]

  • 40. High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant.
    de Lima M, van Besien K, Gajewski J, Khouri I, Andersson B, Korbling M, Champlin R, Giralt S.
    Bone Marrow Transplant; 2000 Aug 24; 26(3):333-8. PubMed ID: 10967575
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 49.